Fayad Al-Haimus։ HI-PEITHO Shows Reduced PE Complications Without Increased Bleeding
Fayad Al-Haimus, Adult Thrombosis Fellow at McMaster University, shared a post on LinkedIn about a recent article by Kenneth Rosenfield et al. published in The New England Journal of Medicine (NEJM):
”The HI-PEITHO trial landed in NEJM Group last week. Worth a read if you manage PE.
The background: intermediate-high-risk PE has always been a difficult call.
Anticoagulation alone felt insufficient for the sickest patients, but systemic thrombolysis carried some bleeding risk as well (approximately 2% intracranial hemorrhage in PEITHO-1) to use routinely.
HI-PEITHO tested low-dose alteplase delivered via catheter directly into the pulmonary artery: 544 patients, 59 sites across the US and Europe.
At 7 days, the primary composite endpoint (PE-related death, cardiopulmonary decompensation, or recurrence) occurred in 4.0% of the catheter-directed thrombolysis group versus 10.3% on anticoagulation alone, roughly a 60% relative risk reduction.
Major bleeding was similar between groups.
A few things worth keeping in mind before updating practice:
- No mortality benefit demonstrated; the signal is in short-term decompensation.
- It remains unclear whether the ultrasound component adds anything over low-dose catheter alteplase alone.
The trial gives the field something it has been lacking; a reasonably powered RCT with a clear signal in a population that has been genuinely hard to manage.”
Title: Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism
Authors: Kenneth Rosenfield, Frederikus A. Klok, Gregory Piazza, Andrew S.P. Sharp, Fionnuala Ní Áinle, Michael R. Jaff, Stefano Barco, Samuel Z. Goldhaber, Nils Kucher, Irene M. Lang, Irene Schmidtmann, Keith M. Sterling, Aleksander Araszkiewicz, Vishal Arora, Rafael Cires-Drouet, John Coghlan, Lukas Hobohm, Wulf D. Ito, Kurt Jacobson, Christoph Kaiser, Grzegorz Kopec, Kristin Marx, Samuel McElwee, Nicolas Meneveau, Peter Monteleone, Jose M. Montero-Cabezas, Christoph B. Olivier, John Park, Marek Roik, Rahul Sakhuja, Andi Tego, Markus Theurl, Gautam Visveswaran, Jan Albert Vos, Michael N. Young, Federico M. Asch, Stavros V. Konstantinides
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 6, 2026, 18:17Aryabhatta Sadhu: Irradiation of Blood Components – From Clinical Indication to Laboratory Release
-
Sep 6, 2026, 18:15Ashenafi Tazebew Amare: A Year of Progress, Transformation and Renewed Commitment
-
Sep 6, 2026, 18:13Emilio Osorio: Can Anticoagulation Be Safely Discontinued After Surgical Left Atrial Appendage Occlusion?
-
Sep 6, 2026, 18:11Razan Alolyani: Our Research on Anticoagulation After Acute Ischemic Stroke Receives 2nd Place
-
Sep 6, 2026, 18:10Chayakrit Krittanawong: Have You Heard of Blood Clots in the Legs?
-
Sep 6, 2026, 18:08Trilok Chand: Microplastics Found in Human Testes and Blood Clots
-
Sep 6, 2026, 18:07Sarah Moharem Elgamal: Cardiovascular Imaging Beyond Anatomy Toward Earlier Risk Prediction
-
Sep 6, 2026, 16:41Christina P.: APS – How it Happens in Your Blood, the Warning Signs, and What to Do about It
-
Sep 6, 2026, 16:33Jose Angel Nicolas Avila: How Tissue Mitochondrial Activity Dictates Macrophage Pool Size